Breaking News

Paladin, Apeiron in Neuroblastoma Pact

January 17, 2013

Paladin granted rights to market APN311 in Canada and Africa

Paladin Labs, Inc. has entered into an exclusive license agreement with Apeiron Biologics for APN311, an antibody-based immunotherapy for children with high-risk neuroblastoma. Paladin has been granted the exclusive rights to market and sell APN311 in Canada and Sub-Saharan Africa. Further details or financial terms were not disclosed.
 
APN311 is a monoclonal chimeric antibody produced in CHO cells targeting the GD2 antigen on neuroblastoma cells and is currently in Phase III development in Europe. Treatment of advanced neuroblastoma patients with APN311 has demonstrated positive clinical activity.
 
"APN311 has shown promise in improving survival rates in the treatment of children diagnosed with neuroblastoma," said Mark Beaudet, interim president and chief executive officer of Paladin Labs. "Paladin is proud to be working with Apeiron to make this important new treatment option available to patients in Canada and Sub-Saharan Africa."
 
"We are very excited to partner with Paladin, one of the leading Canadian specialty pharmaceutical companies, given its experience in rare and orphan diseases as well as its emerging focus in oncology. Paladin is well positioned to make APN311 a success in its territories," said Hans Loibner, president and chief executive officer of Apeiron Biologics.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research